{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:18Z","timestamp":1791414618918,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T00:00:00Z","timestamp":1137628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00280-005-0174-5","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T11:05:16Z","timestamp":1137582316000},"page":"396-401","source":"Crossref","is-referenced-by-count":14,"title":["Dihydropyrimidine dehydrogenase deficiency in an Indian population"],"prefix":"10.1007","volume":"58","author":[{"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Mattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Carollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ezzeldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Diasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,19]]},"reference":[{"issue":"11","key":"174_CR1","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","volume":"16","author":"Meta-analysis Group in Cancer","year":"1998","unstructured":"Meta-analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16(11):3537\u20133541","journal-title":"J Clin Oncol"},{"key":"174_CR2","doi-asserted-by":"crossref","unstructured":"Van Kuilenburg AB et al (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101(3):253\u2013258","DOI":"10.1002\/ijc.10599"},{"issue":"1","key":"174_CR3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9258(18)65251-2","volume":"221","author":"ES Canellakis","year":"1956","unstructured":"Canellakis ES (1956) Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation. J Biol Chem 221(1):315\u2013322","journal-title":"J Biol Chem"},{"issue":"2","key":"174_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0163-7258(90)90080-L","volume":"48","author":"GC Daher","year":"1990","unstructured":"Daher GC, Harris BE, Diasio RB (1990) Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48(2):189\u2013222","journal-title":"Pharmacol Ther"},{"issue":"1","key":"174_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81(1):47\u201351","journal-title":"J Clin Invest"},{"issue":"10","key":"174_CR6","first-page":"2672","volume":"5","author":"RB Diasio","year":"1999","unstructured":"Diasio RB, Johnson MR (1999) Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5(10):2672\u20132673","journal-title":"Clin Cancer Res"},{"issue":"3","key":"174_CR7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO;2-F","volume":"68","author":"BE Harris","year":"1991","unstructured":"Harris BE, Carpenter JT, Diasio RB (1991) Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 68(3):499\u2013501","journal-title":"Cancer"},{"issue":"1","key":"174_CR8","first-page":"83","volume":"24","author":"GB Morrison","year":"1997","unstructured":"Morrison GB et al (1997) Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 24(1):83\u201388","journal-title":"Oncol Nurs Forum"},{"issue":"3","key":"174_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R (2004) Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 4(3):181\u2013189","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"174_CR10","first-page":"768","volume":"8","author":"MR Johnson","year":"2002","unstructured":"Johnson MR, Wang K, Diasio RB (2002) Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8(3):768\u2013774","journal-title":"Clin Cancer Res"},{"issue":"11","key":"174_CR11","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC et al (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12(11):2248\u20132253","journal-title":"J Clin Oncol"},{"issue":"2","key":"174_CR12","first-page":"325","volume":"4","author":"Z Lu","year":"1998","unstructured":"Lu Z et al (1998) Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 4(2):325\u2013329","journal-title":"Clin Cancer Res"},{"key":"174_CR13","doi-asserted-by":"crossref","unstructured":"Mattison LK et al (2005) Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians. Proceedings of the 2005 ASCO Annual Meeting 2005:2004","DOI":"10.1200\/jco.2005.23.16_suppl.2004"},{"issue":"2","key":"174_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","volume":"696","author":"MR Johnson","year":"1997","unstructured":"Johnson MR et al (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 696(2):183\u2013191","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"8","key":"174_CR15","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","volume":"10","author":"LK Mattison","year":"2004","unstructured":"Mattison LK et al (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10(8):2652\u20132658","journal-title":"Clin Cancer Res"},{"issue":"10","key":"174_CR16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725\u2013730","journal-title":"N Engl J Med"},{"issue":"1","key":"174_CR17","first-page":"197","volume":"50","author":"BE Harris","year":"1990","unstructured":"Harris BE et al (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50(1):197\u2013201","journal-title":"Cancer Res"},{"key":"174_CR18","unstructured":"Meretek Diagnostics I (2002) In: Meretek UBiT-IR300: 13CO2 urea breath analyzer instruction manual. Lafayette, CO, Meretek Diagnostics, pp A1\u2013A2"},{"issue":"14","key":"174_CR19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0261-5614(95)80012-3","volume":"\u00a0","author":"S Amarri","year":"1995","unstructured":"Amarri S, Weaver LT (1995) 13C-breath tests to measure fat and carbohydrate digestion in clincial practice. Clin Nutr (14):149\u2013154","journal-title":"Clin Nutr"},{"issue":"22","key":"174_CR20","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53(22):5433\u20135438","journal-title":"Cancer Res"},{"key":"174_CR21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"issue":"1","key":"174_CR22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","volume":"306","author":"H Ezzeldin","year":"2002","unstructured":"Ezzeldin H et al (2002) A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 306(1):63\u201373","journal-title":"Anal Biochem"},{"issue":"4","key":"174_CR23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215\u2013237","journal-title":"Clin Pharmacokinet"},{"key":"174_CR24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","volume":"41","author":"MR Johnson","year":"2001","unstructured":"Johnson MR, Diasio RB (2001) Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151\u2013157","journal-title":"Adv Enzyme Regul"},{"issue":"12","key":"174_CR25","first-page":"4705","volume":"6","author":"AB Kuilenburg van","year":"2000","unstructured":"van Kuilenburg AB et al (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6(12):4705\u20134712","journal-title":"Clin Cancer Res"},{"issue":"24","key":"174_CR26","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1016\/S0021-9258(18)41899-6","volume":"267","author":"ZH Lu","year":"1992","unstructured":"Lu ZH, Zhang R, Diasio RB (1992) Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267(24):17102\u201317109","journal-title":"J Biol Chem"},{"issue":"8","key":"174_CR27","first-page":"3021","volume":"9","author":"H Ezzeldin","year":"2003","unstructured":"Ezzeldin H et al (2003) Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 9(8):3021\u20133028","journal-title":"Clin Cancer Res"},{"issue":"4","key":"174_CR28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14622416.3.4.485","volume":"3","author":"LK Mattison","year":"2002","unstructured":"Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3(4):485\u2013492","journal-title":"Pharmacogenomics"},{"issue":"9","key":"174_CR29","first-page":"2832","volume":"7","author":"M Raida","year":"2001","unstructured":"Raida M et al (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 7(9):2832\u20132839","journal-title":"Clin Cancer Res"},{"key":"174_CR30","doi-asserted-by":"crossref","unstructured":"Ezzeldin HH et al (2005) Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11(24) (in press)","DOI":"10.1158\/1078-0432.CCR-05-1520"},{"issue":"3","key":"174_CR31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","volume":"10","author":"ES Collie-Duguid","year":"2000","unstructured":"Collie-Duguid ES et al (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10(3):217\u2013223","journal-title":"Pharmacogenetics"},{"issue":"6","key":"174_CR32","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2125.2002.01604.x","volume":"53","author":"SI Hamdy","year":"2002","unstructured":"Hamdy SI et al (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53(6):596\u2013603","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"174_CR33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2125.2000.00242.x","volume":"50","author":"JM Morsman","year":"2000","unstructured":"Morsman JM et al (2000) Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol 50(3):269\u2013272","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"174_CR34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","volume":"92","author":"K Yamaguchi","year":"2001","unstructured":"Yamaguchi K et al (2001) Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn J Cancer Res 92(3):337\u2013342","journal-title":"Jpn J Cancer Res"},{"issue":"2","key":"174_CR35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00007691-199904000-00002","volume":"21","author":"DR Sohn","year":"1999","unstructured":"Sohn DR, Cho MS, Chung PJ (1999) Dihydropyrimidine dehydrogenase activity in a Korean population. Ther Drug Monit 21(2):152\u2013154","journal-title":"Ther Drug Monit"},{"issue":"2","key":"174_CR36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","volume":"46","author":"SA Ridge","year":"1998","unstructured":"Ridge SA et al (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46(2):151\u2013156","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"174_CR37","first-page":"325","volume":"22","author":"E Gross","year":"2003","unstructured":"Gross E et al (2003) High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol 22(2):325\u2013332","journal-title":"Int J Oncol"},{"issue":"5","key":"174_CR38","first-page":"1149","volume":"7","author":"AB Kuilenburg van","year":"2001","unstructured":"van Kuilenburg AB et al (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7(5):1149\u20131153","journal-title":"Clin Cancer Res"},{"issue":"2","key":"174_CR39","first-page":"291","volume":"5","author":"RA Humerickhouse","year":"1999","unstructured":"Humerickhouse RA et al (1999) Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 5(2):291\u2013298","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-005-0174-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-005-0174-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T15:28:08Z","timestamp":1626967688000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-005-0174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,19]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s00280-005-0174-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,19]]}}}